BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Cancer / Immunology

Sichuan Kelun-Biotech Biopharmaceutical Secures China IND Clearance For PD 1 x VEGF Bispecific SKB118 In Advanced Solid Tumours

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990.HK) announced that it has received a clinical trial notice from t...

May 14, 2026 | News

Inhibrx Biosciences Reports Strong Phase 2 Response Data For INBRX 106 And Pembrolizumab Combination In Head And Neck Cancer

Interim analyses show INBRX-106 + pembrolizumab achieved a 44.0% confirmed Objective Response Rate (cORR): In the prelimina...

May 13, 2026 | News

Hengrui Pharma And Bristol Myers Squibb Forge $15.2 Billion Strategic Alliance Across Oncology And Immunology

Landmark collaboration leverages complementary capabilities to drive speed in early innovation and help advance medicines for patients worldwide Agreement...

May 13, 2026 | News

Rznomics Secures FDA RMAT Designation For RNA Editing Therapy RZ 001 In Liver Cancer

RMAT designation based on promising Phase 1b/2a clinical data, including safety profile and preliminary response rates, ...

May 11, 2026 | News

Harbour BioMed Secures US FDA Clearance For Phase I Trial Of Bispecific Cancer Antibody HBM7004

Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics i...

May 11, 2026 | News

Cartography Biosciences Secures Strategic Investment From Samsung Ventures To Advance Precision Oncology Pipeline

Cartography Biosciences and Samsung Ventures announced a strategic investment to support the advancement of Cartography’s differentiated oncology pip...

May 08, 2026 | News

Australia Registers PEDMARQSI As First Approved Therapy To Prevent Cisplatin Related Hearing Loss In Children

PEDMARQSI® is now TGA registered in Australia for the prevention of ototoxicity induced by cisplatin chemotherapy in patients 1 month to <18 ...

May 07, 2026 | News

Cellenkos Advances CK0802 Into Phase 1b 2a Trial Following FDA Clearance For Steroid Refractory GVHD

Multicenter, open-label study will evaluate the safety and preliminary efficacy of CK0802, a first-in-class, off-the-shelf Treg therapy, in patients with s...

May 06, 2026 | News

Thermo Fisher Introduces Gibco CTS DynaXS Single Use Bioreactor For Scalable Cell Therapy Manufacturing

New Gibco™ CTS™ DynaXS™ Single Use Bioreactor supports flexible, cGMP-ready cell expansion from process development to clinical productio...

May 05, 2026 | News

EnGeneIC Doses First Patient In Trial Targeting Recurrent Glioblastoma

EnGeneIC announced that the first patient has been dosed in its clinical trial evaluating EnGeneIC’s investigational EGFR-targeted EDV™ (EnGene...

May 05, 2026 | News

Olympus Corporation Partners With EndoRobotics To Advance Global Access To Robot Assisted Endoscopic Care

Partnership Aimed at Expanding Patient Access to Advanced EndoTherapeutic Procedures Olympus Corporation (Olympus), a global MedTech company co...

May 05, 2026 | News

Huahui Health And BeOne Medicines Forge Global Deal For Trispecific Antibody HH160

Huahui Health announced that it has entered into a global exclusive option, license and collaboration agreement with BeOne Medicines for HH160, a...

May 04, 2026 | News

Henlius And Organon Secure European Approval For First Pertuzumab Biosimilar POHERDY

Shanghai Henlius Biotech, Inc. (2696.HK), and Organon (NYSE: OGN) today announced the European Commission (EC) has granted marketing authorization for POHE...

May 01, 2026 | News

Insilico Medicine Secures IND Clearance For Rentosertib Inhalation Solution To Advance Targeted IPF Therapy

Following positive Phase IIa results for oral Rentosertib in GENESIS-IPF with good tolerability, a favorable PK profile, and dose-dependent efficacy impr...

April 30, 2026 | News

Stay Connected